Catherine Gerard
Waver, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 15, 2025
Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 04, 2025
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: November 05, 2024
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
Journal: Infectious diseases and therapy
Published: February 01, 2024
Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate.
Journal: Clinical & translational immunology
Published: October 08, 2021
Microenvironment-derived ADAM28 prevents cancer dissemination.
Journal: Oncotarget
Published: July 27, 2018
ADAM10 mediates malignant pleural mesothelioma invasiveness.
Journal: Oncogene
Published: July 12, 2018
Neutrophil-Derived Interleukin 16 in Premetastatic Lungs Promotes Breast Tumor Cell Seeding.
Journal: Cancer growth and metastasis
Published: April 04, 2017
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: September 02, 2015
The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
Journal: Cancer immunology, immunotherapy : CII
Published: July 31, 2015
Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys.
Journal: Journal of applied toxicology : JAT
Published: January 27, 2014
Last Updated: 09/26/2026